Mylan Encounters "Irrational Pricing" In Duragesic Generics Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Pricing pressure for fentanyl transdermal resulted from "premarketing" by other ANDA filers and regulatory uncertainty that gave "authorized" generic marketer Sandoz an advantage, Mylan CEO says. Timing of other generic entrants and potential supply problems for J&J/Sandoz could allow Mylan to recover lost profits.
You may also be interested in...
FDA Rejects Noven Fentanyl Patch ANDA Due To Safety Concerns
The agency will cease reviewing Noven/Endo’s generic version of J&J’s Duragesic chronic pain therapy due to a higher drug content in the pending ANDA.
FDA Rejects Noven Fentanyl Patch ANDA Due To Safety Concerns
The agency will cease reviewing Noven/Endo’s generic version of J&J’s Duragesic chronic pain therapy due to a higher drug content in the pending ANDA.
Ultracet Generics Launch: Par Goes "At Risk," Ivax Has "Authorized" Generic
Patent litigation between Par and J&J is pending in Newark, N.J. federal court. Par received ANDA approval for the tramadol/acetaminophen combination the same day the 30-month stay expired.